Summary Summary Two generic preparations
Two generic preparations of clozapine have been licensed in the UK. of clozapine have been licensed in the UK. The bioequivalence of these products The bioequivalence of these products compared with Clozaril compared with Clozaril 1 1 has not been has not been unequivocally demonstrated.Clinical unequivocally demonstrated.Clinical equivalence has also been questioned.The equivalence has also been questioned.The objective ofthis study was to determine objective ofthis study was to determine clinical outcomes for all patients switched clinical outcomes for all patients switched from Clozaril from Clozaril 1 1 to a generic formulation in to a generic formulation in one mental health service.We examined one mental health service.We examined dosage data and Clinical Global dosage data and Clinical Global Impression (CGI) of Severity of Illness Impression (CGI) of Severity of Illness scores for 337 patients before and after scores for 337 patients before and after the switch and CGIchange scores after the the switch and CGIchange scores after the switch.There was no evidence of clinical switch.There was no evidence of clinical deterioration or need to use higher deterioration or need to use higher dosages.Generic clozapine is not inferior dosages.Generic clozapine is not inferior to Clozaril to Clozaril 1 1 . .
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Clozapine is indicated in treatment-resistant Clozapine is indicated in treatment-resistant schizophrenia, where it is uniquely effective schizophrenia, where it is uniquely effective (National Institute for Clinical Excellence, (National Institute for Clinical Excellence, 2003) . Clozapine has been available in the 2003). Clozapine has been available in the UK for 15 years under the brand name UK for 15 years under the brand name Clozaril Clozaril 1 1 . Two branded generic products . Two branded generic products have recently been licensed. Standard bio-have recently been licensed. Standard bioequivalence studies are difficult to conduct equivalence studies are difficult to conduct for clozapine, where small doses can cause for clozapine, where small doses can cause profound hypotension and tachycardia in profound hypotension and tachycardia in healthy volunteers; bioequivalence across healthy volunteers; bioequivalence across the dosage range has not been the dosage range has not been unequivocally demonstrated for the avail-unequivocally demonstrated for the available products Ereshefsky & able products (Anon, 2001; Ereshefsky & Glazier, 2001) . Glazier, 2001) .
Clinical equivalence has also been ques-Clinical equivalence has also been questioned . Five papers reporting tioned . Five papers reporting on outcomes in a total of 131 patients on outcomes in a total of 131 patients have been published. One, a case series have been published. One, a case series (Mofsen & Balter, 2001) , reported a high (Mofsen & Balter, 2001) , reported a high relapse rate and one (Kluznik relapse rate and one (Kluznik et al et al, 2001 (Kluznik et al et al, ), , 2001 ), which was sponsored by the patent holder, which was sponsored by the patent holder, reported a trend towards deterioration. reported a trend towards deterioration.
These papers have been widely cited as These papers have been widely cited as proof that switching patients to generic proof that switching patients to generic clozapine is a high-risk strategy. The work clozapine is a high-risk strategy. 2003) , both sponsored by a generic manufacturer, did not replicate by a generic manufacturer, did not replicate these findings. This work is less well these findings. This work is less well known. known.
We report on our experiences of switch-We report on our experiences of switching all patients in a single mental health ing all patients in a single mental health trust from Clozaril trust from Clozaril 1 1 (Novartis Pharmaceu-(Novartis Pharmaceuticals, Surrey, UK) to generic clozapine. ticals, Surrey, UK) to generic clozapine.
METHOD METHOD
All patients ( All patients (n n¼337) were switched from 337) were switched from Clozaril Clozaril 1 1 to generic clozapine (Zaponex to generic clozapine (Zaponex 1 1 ; ; IVAX Pharmaceuticals, London, UK). There IVAX Pharmaceuticals, London, UK). There were no exclusions. were no exclusions.
The following data were collected for The following data were collected for each patient: each patient:
(a) (a) at baseline (1 month before the switch):
at baseline (1 month before the switch): name, gender, ethnicity, age, duration name, gender, ethnicity, age, duration of treatment with Clozaril of treatment with Clozaril 1 1 , dose and , dose and Clinical Global Impression of Severity Clinical Global Impression of Severity of Illness (CGI; . of Illness (CGI; .
(b) (b) at follow up (3 months after the at follow up (3 months after the switch): dose, CGIs and Clinical switch): dose, CGIs and Clinical Global Impression of change over the Global Impression of change over the past 3 months (CGIc). The CGIc score past 3 months (CGIc). The CGIc score was chosen as the primary outcome was chosen as the primary outcome measure, as it is simple to complete measure, as it is simple to complete and detects change that is clinically and detects change that is clinically meaningful. meaningful.
Patients who remained on generic clo-Patients who remained on generic clozapine at the point of follow-up were zapine at the point of follow-up were compared with those who dropped out of compared with those who dropped out of treatment (independent treatment (independent t t-test for continu--test for continuous data and ous data and w w 2 2 for categorical data). for categorical data). Patients who remained on treatment were Patients who remained on treatment were divided into 3 groups depending on the divided into 3 groups depending on the duration of clozapine treatment at the time duration of clozapine treatment at the time of the switch ( of the switch (5 518, 18-52, 18, 18-52, 4 452 weeks). 52 weeks). The CGI severity scores and doses of cloza-The CGI severity scores and doses of clozapine before and after switching were com-pine before and after switching were compared using paired-samples pared using paired-samples t t-tests. The -tests. The CGIs score after switching was then sub-CGIs score after switching was then subtracted from the baseline score to give an tracted from the baseline score to give an estimate of change. This calculated change estimate of change. This calculated change score was compared with the clinician-score was compared with the cliniciancompleted CGIc score using Pearson's cor-completed CGIc score using Pearson's correlation, a test of internal validity. relation, a test of internal validity.
RESULTS

Of the 337 patients switched from Cloz-Of the 337 patients switched from Clozaril aril 1 1 to generic clozapine, 304 (90.2%) to generic clozapine, 304 (90.2%) remained on treatment 3 months later; 26 remained on treatment 3 months later; 26 patients (7.7%) stopped treatment; 5 patients (7.7%) stopped treatment; 5 (1.5%) moved out of the area and 2 (1.5%) moved out of the area and 2 (0.6%) died. Completers had been on (0.6%) died. Completers had been on treatment for longer at the point of switch treatment for longer at the point of switch (mean 62.6 (mean 62.6 v v. 23 months, . 23 months, t t¼3.778, 3.778, P P5 50.001) and were receiving a higher dose 0.001) and were receiving a higher dose (mean 443 mg/day (mean 443 mg/day v v. 340 mg/day, . 340 mg/day, t t¼2.559, 2.559, P P¼0.011) than those who stopped treat-0.011) than those who stopped treatment. There were no differences with ment. There were no differences with respect to age or gender. respect to age or gender.
Mean CGIs scores before and after the Mean CGIs scores before and after the switch were: patients treated for switch were: patients treated for 5 Significant dose increases were seen in Significant dose increases were seen in those who had been treated for those who had been treated for 5 518 weeks 18 weeks (mean 327 mg before, 380 mg after, (mean 327 mg before, 380 mg after, t t¼3.732, 3.732, P P¼0.001). No significant dosage 0.001). No significant dosage adjustments were seen in other patients. adjustments were seen in other patients.
The CGIc scores after switching are The CGIc scores after switching are shown in Fig. 1 . The CGIc score was corre-shown in Fig. 1 
DISCUSSION DISCUSSION
We found no evidence of dosage escalation We found no evidence of dosage escalation or clinical deterioration in patients switched or clinical deterioration in patients switched from branded Clozaril from branded Clozaril 1 1 to generic cloza-to generic clozapine. This is consistent with the findings pine. This is consistent with the findings of (2001). Collectively, these studies report on outcomes in a total of 131 report on outcomes in a total of 131 patients, less than half the number in our patients, less than half the number in our cohort. Individually, they lack the power cohort. Individually, they lack the power to detect even large treatment effects. Their to detect even large treatment effects. Their different findings can easily be explained by different findings can easily be explained by combinations of small sample size, hetero-combinations of small sample size, heterogeneous patient groups, the use of different geneous patient groups, the use of different outcome measures and patient selection, outcome measures and patient selection, sponsorship and publication bias. sponsorship and publication bias.
Almost 8% of patients discontinued Almost 8% of patients discontinued clozapine after switching but before the clozapine after switching but before the 3-month follow-up period was complete. 3-month follow-up period was complete. Although this attrition rate seems high, Although this attrition rate seems high, it is consistent with the meta-analysis of it is consistent with the meta-analysis of Wahlbeck Wahlbeck et al et al (1999); 14.8% of patients (1999); 14.8% of patients in short-term randomised controlled trials in short-term randomised controlled trials and 39% of patients randomised to and 39% of patients randomised to treatment with clozapine in long-term ran-treatment with clozapine in long-term randomised controlled trials 'left the study domised controlled trials 'left the study early'. early'.
Patients who were still taking clozapine Patients who were still taking clozapine 3 months after switching to the generic 3 months after switching to the generic preparation tended to improve. This preparation tended to improve. This improvement was highly statistically signif-improvement was highly statistically significant but clinically small. Our results do not icant but clinically small. Our results do not constitute proof that the generic prepara-constitute proof that the generic preparation is superior to Clozaril tion is superior to Clozaril 1 1 , simply that it , simply that it is not inferior. is not inferior.
By using a CGIc score of much or very By using a CGIc score of much or very much worse as a proxy for relapse, three much worse as a proxy for relapse, three patients could be considered to have patients could be considered to have relapsed. In addition, 16 patients were relapsed. In addition, 16 patients were rated as minimally worse. Wahlbeck rated as minimally worse. Wahlbeck et al et al (1999) found that 7.5% of patients in (1999) found that 7.5% of patients in long-term studies relapsed. Our findings long-term studies relapsed. Our findings are consistent with this. are consistent with this.
As expected, there was upwards dosage As expected, there was upwards dosage drift in the group of patients who had been drift in the group of patients who had been treated for treated for 5 518 weeks at baseline. Such 18 weeks at baseline. Such patients are being initiated and stabilised patients are being initiated and stabilised on treatment. There was no dosage drift on treatment. There was no dosage drift in those who had been treated for in those who had been treated for 4 418 18 weeks at baseline. weeks at baseline.
Implications for clinical practice Implications for clinical practice
Large numbers of patients around the Large numbers of patients around the world have been switched to generic world have been switched to generic preparations of clozapine (Ereshefsky & preparations of clozapine (Ereshefsky & Glazer, 2001) . The number of publications . The number of publications reporting on outcome is very small. Our reporting on outcome is very small. Our study alone triples the number of patients study alone triples the number of patients for whom data are available. It may be true for whom data are available. It may be true that generic preparations are not proven that generic preparations are not proven exactly bioequivalent to branded Clozaril exactly bioequivalent to branded Clozaril (2001) were widely cited by the original patent holders in a campaign original patent holders in a campaign aimed at protecting their monopoly. The aimed at protecting their monopoly. The selective use of studies reporting on the effi-selective use of studies reporting on the efficacy and safety of drugs makes evidence-cacy and safety of drugs makes evidencebased decision-making impossible. The based decision-making impossible. The methods used by the pharmaceutical indus-methods used by the pharmaceutical industry must be challenged. try must be challenged.
Limitations Limitations
The CGIc scores might not detect small The CGIc scores might not detect small changes in psychopathology, thus underes-changes in psychopathology, thus underestimating the number of patients whose timating the number of patients whose mental state changed after the switch. Pa-mental state changed after the switch. Patients were followed-up for only 3 months tients were followed-up for only 3 months after switching; nothing is known about after switching; nothing is known about outcomes beyond this point. Changes in outcomes beyond this point. Changes in other prescribed medicines or life events other prescribed medicines or life events that may have affected outcome were not that may have affected outcome were not controlled for. controlled for.
Lam,Y. W., Ereshefsky, L., Toney, G. B., Lam,Y. W., Ereshefsky, L., Toney, G. B., et al et al (2001) Fig. 1 Clinical Global Impression (CGI) change scores 3 months after switching from Clozaril Clinical Global Impression (CGI) change scores 3 months after switching from Clozaril 1 1 to generic to generic clozapine.Overall,16 patients were rated as minimally worse and 3 as much worse.Of the 3 patients rated to be clozapine.Overall,16 patients were rated as minimally worse and 3 as much worse.Of the 3 patients rated to be much worse, 2 were known to be partially or non-compliant and 1 was chronically physically unwell; 8 of the 16 much worse, 2 were known to be partially or non-compliant and 1 was chronically physically unwell; 8 of the 16 patients rated as minimally worse had 'spontaneous explanations' recorded on their rating form, such as family patients rated as minimally worse had 'spontaneous explanations' recorded on their rating form, such as family bereavement, compliance in doubt, acutely physically unwell and lost mental health review tribunal. bereavement, compliance in doubt, acutely physically unwell and lost mental health review tribunal.
